Connect your AI

Biohaven BHVN Success-based milestone payments, based on regulatory approval

Other financials

Income statement

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Returns & leverage

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:SuccessBasedMilestonePaymentsToBePaidBasedOnRegulatoryApproval.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's success-based milestone payments, based on regulatory approval.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biohaven's success-based milestone payments, based on regulatory approval?: Biohaven (BHVN) reported success-based milestone payments, based on regulatory approval of $185M in Q1 2026.
How has Biohaven's success-based milestone payments, based on regulatory approval changed year-over-year?: Biohaven's success-based milestone payments, based on regulatory approval decreased by 0.0% year-over-year, from $185M to $185M.